A Multicenter, Randomized, Double-Blind, Study Comparing the Efficacy and Safety of Continuing Versus Withdrawing Adalimumab Therapy in Maintaining Remission in Subjects With Non-Radiographic Axial Spondyloarthritis

Trial Profile

A Multicenter, Randomized, Double-Blind, Study Comparing the Efficacy and Safety of Continuing Versus Withdrawing Adalimumab Therapy in Maintaining Remission in Subjects With Non-Radiographic Axial Spondyloarthritis

Completed
Phase of Trial: Phase III/IV

Latest Information Update: 16 Apr 2018

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Spondylarthritis
  • Focus Therapeutic Use
  • Acronyms Ability-3
  • Sponsors AbbVie
  • Most Recent Events

    • 08 Nov 2017 Results assessing predictors of remission maintenance (through week 68) in nr-axSpA patients who achieved remission after open-label adalimumab treatment and were subsequently randomized to continuation or withdrawal of Adalimumab therapy, presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting.
    • 08 Nov 2017 Results assessing potential differences in patient (pt) categorization using different minimum values for hsCRP in the ASDAS calculation and different definitions of disease flare, presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
    • 08 Nov 2017 Primary endpoint (The proportion of participants who do not experience a flare during period 2 by Week 68 of the study where a flare is defined as having any 2 consecutive study visits with ASDAS 2.1) has been met, according to the results presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top